FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

A correction has been published: N Engl J Med 1997;336(9):670.

Previous Volume 335:1261-1267 October 24, 1996 Number 17 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article Related Article PubMed Citation

ABSTRACT

Background Kaposi's sarcoma is the most common cancer in patients with the acquired immunodeficiency syndrome (AIDS). Recently, certain preparations of human chorionic gonadotropin (hCG) have been shown to inhibit the growth of Kaposi's sarcoma cell lines in vitro and in immunodeficient mice.

Methods After in vitro evaluation of four commercially available hCG preparations, the most active product was evaluated in 36 patients with AIDS-related Kaposi's sarcoma. In a phase 1–2 trial, 24 patients received intralesional injections of hCG three times a week for two weeks at doses of 250, 500, 1000, or 2000 IU (6 patients each). In each patient three nodular lesions were injected, two with the drug and one with diluent alone. In a double-blind trial, 12 additional patients were randomly assigned to receive intralesional injections of 2000 IU of hCG or diluent alone (6 patients each; two lesions per patient). At the conclusion of therapy, the lesions were measured, their gross appearance assessed, and biopsy specimens evaluated.

Results A.P.L. (Wyeth–Ayerst), which had the most in vitro activity against Kaposi's sarcoma cell lines, was selected for the clinical investigation. Treatment with A.P.L. was well tolerated at all doses. In the cohorts given 250, 500, 1000, and 2000 IU, 1, 5, 5, and 10 of the 12 injected lesions responded, respectively (P = 0.03 for trend). Complete tumor regression was observed in one lesion each at the 250-IU and 500-IU doses, in two lesions given the 1000-IU dose, and in five lesions given the 2000-IU dose. In the double-blind study, none of the 12 lesions in the six patients injected with diluent had responses, as compared with 10 of the 12 lesions in the six patients injected with hCG (P = 0.015). Microscopical evidence of apoptosis was observed only in hCG-treated lesions. The percentage of cells that died increased in a dose-dependent manner (P<0.001). Serum levels of follicle-stimulating hormone (P = 0.002) and luteinizing hormone (P = 0.001) declined after the last injection of hCG, but there was no effect on these hormones in the diluent-treated patients.

Conclusions The intralesional injection of hCG induces the regression of AIDS-related Kaposi's sarcoma lesions in a dose-dependent manner. The response of these tumors appears to be mediated by the induction of apoptosis.

Source Information

From the Departments of Internal Medicine (P.S.G., A.T., T.Z., B.M.E., A.M.L.) and Pharmacy (S.L.), University of Southern California School of Medicine, Los Angeles; the Institute of Human Virology, University of Maryland, Baltimore (Y.L.-I., J.L.B., R.C.G.); the Department of Infectious Diseases, St. Pierre Hospital, Université Libre de Bruxelles, Brussels, Belgium (P.H.); and the Gynecology and Obstetrical Medical Center, Paris (J.M.B.).

Address reprint requests to Dr. Gill at the University of Southern California, Norris Cancer Hospital and Research Institute, 1441 Eastlake Ave., Rm. 162, Los Angeles, CA 90033.

Full Text of this Article

Related Letters:

Intralesional Human Chorionic Gonadotropin for Kaposi's Sarcoma
Harris P. J., Russo I. H., Grulich A. E., Kaldor J. M., Gill P. S., Lunardi-Iskandar Y., Gallo R. C., Krown S. E., Rabkin C. S.
Extract | Full Text  
N Engl J Med 1997; 336:1187-1189, Apr 17, 1997. Correspondence

This article has been cited by other articles:

• Lopez, D., Sekharam, M., Coppola, D., Carter, W. B. (2008). Purified human chorionic gonadotropin induces apoptosis in breast cancer. Molecular Cancer Therapeutics 7: 2837-2844 [Abstract] [Full Text]  
• Stebbing, J., Mazhar, D., Lewis, R., Palmieri, C., Hatzimichael, E., Nelson, M., Gazzard, B., Bower, M. (2006). The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi's sarcoma. Ann Oncol 17: 503-506 [Abstract] [Full Text]  
• Malatos, S., Neubert, H., Kicman, A. T., Iles, R. K. (2005). Identification of Placental Transforming Growth Factor-{beta} and Bikunin Metabolites as Contaminants of Pharmaceutical Human Chorionic Gonadotrophin Preparations by Proteomic Techniques. Mol. Cell. Proteomics 4: 984-992 [Abstract] [Full Text]  
• Butler, S. A., Iles, R. K. (2003). Ectopic Human Chorionic Gonadotropin {beta} Secretion by Epithelial Tumors and Human Chorionic Gonadotropin {beta}-Induced Apoptosis in Kaposi's Sarcoma: Is There a Connection?. Clin. Cancer Res. 9: 4666-4673 [Abstract] [Full Text]  
• Matzuk, M. M., DeMayo, F. J., Hadsell, L. A., Kumar, T. R. (2003). Overexpression of Human Chorionic Gonadotropin Causes Multiple Reproductive Defects in Transgenic Mice. Biol. Reprod. 69: 338-346 [Abstract] [Full Text]  
• Dourmishev, L. A., Dourmishev, A. L., Palmeri, D., Schwartz, R. A., Lukac, D. M. (2003). Molecular Genetics of Kaposi's Sarcoma-Associated Herpesvirus (Human Herpesvirus 8) Epidemiology and Pathogenesis. Microbiol. Mol. Biol. Rev. 67: 175-212 [Abstract] [Full Text]  
• Pfeffer, U., Bisacchi, D., Morini, M., Benelli, R., Minghelli, S., Vacca, A., Noonan, D. M., Albini, A. (2002). Human Chorionic Gonadotropin Inhibits Kaposi's Sarcoma Associated Angiogenesis, Matrix Metalloprotease Activity, and Tumor Growth. Endocrinology 143: 3114-3121 [Abstract] [Full Text]  
• Liu, P. Y., Wishart, S. M., Handelsman, D. J. (2002). A Double-Blind, Placebo-Controlled, Randomized Clinical Trial of Recombinant Human Chorionic Gonadotropin on Muscle Strength and Physical Function and Activity in Older Men with Partial Age-Related Androgen Deficiency. J. Clin. Endocrinol. Metab. 87: 3125-3135 [Abstract] [Full Text]  
• Antman, K., Chang, Y. (2000). Kaposi's Sarcoma. NEJM 342: 1027-1038 [Full Text]  
• Simonart, T., Hermans, P., Van Vooren, J.-P., Meuris, S. (1999). Paradoxical Pro-Kaposi's Sarcoma Activity of Preparations of Human Chorionic Gonadotropin. Blood 94: 376-377 [Full Text]  
• Lee-Huang, S., Huang, P. L., Sun, Y., Huang, P. L., Kung, H.-f., Blithe, D. L., Chen, H.-C. (1999). Lysozyme and RNases as anti-HIV components in beta -core preparations of human chorionic gonadotropin. Proc. Natl. Acad. Sci. USA 96: 2678-2681 [Abstract] [Full Text]  
• Masood, R., McGarvey, M. E., Zheng, T., Cai, J., Arora, N., Smith, D. L., Sloane, N., Gill, P. S. (1999). Antineoplastic Urinary Protein Inhibits Kaposi's Sarcoma and Angiogenesis In Vitro and In Vivo. Blood 93: 1038-1044 [Abstract] [Full Text]  
• Darzynkiewicz, Z. (1999). The Butler Did It: Search for Killer(s) of Kaposi's Sarcoma Cells in Preparations of Human Chorionic Gonadotropin. JNCI J Natl Cancer Inst 91: 104-106 [Full Text]  
• Samaniego, F., Bryant, J. L., Liu, N., Karp, J. E., Sabichi, A. L., Thierry, A., Lunardi-Iskandar, Y., Gallo, R. C. (1999). Induction of Programmed Cell Death in Kaposi's Sarcoma Cells by Preparations of Human Chorionic Gonadotropin. JNCI J Natl Cancer Inst 91: 135a-143a [Abstract] [Full Text]  
• Bird, J., Li, X., Lei, Z. M., Sanfilippo, J., Yussman, M. A., Rao, Ch. V. (1998). Luteinizing Hormone and Human Chorionic Gonadotropin Decrease Type 2 5{alpha}-Reductase and Androgen Receptor Protein Levels in Women's Skin. J. Clin. Endocrinol. Metab. 83: 1776-1782 [Abstract] [Full Text]  
• Grossmann, M., Weintraub, B. D., Szkudlinski, M. W. (1997). Novel Insights into the Molecular Mechanisms of Human Thyrotropin Action: Structural, Physiological, and Therapeutic Implications for the Glycoprotein Hormone Family. Endocr. Rev. 18: 476-501 [Abstract] [Full Text]  
• Harris, P. J., Russo, I. H., Grulich, A. E., Kaldor, J. M., Gill, P. S., Lunardi-Iskandar, Y., Gallo, R. C., Krown, S. E., Rabkin, C. S. (1997). Intralesional Human Chorionic Gonadotropin for Kaposi's Sarcoma. NEJM 336: 1187-1189 [Full Text]  
• Krown, S. E. (1996). Kaposi's Sarcoma -- What's Human Chorionic Gonadotropin Got to Do with It?. NEJM 335: 1309-1310 [Full Text]